Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug

Karuna Therapeutics has ticked another task off the to-do list for its blockbuster-in-waiting KarXT, posting phase 1b data that counter concerns about the effect of the schizophrenia therapy on blood pressure.